LAB on XNAS, Health Care, Standard BioTools Inc., job postings
Measures activity, not value. Not investment advice.
Revenue fell 22% over 12 months and the stock lost 51%, though net income hit $133.1M.
BadInstitutional holders fell to 104 from 140, down 26%
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
expected around 7 Jan 2027 (an estimate: a year ago it reported on 8 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $19.4M, net income $13.5M.
31 Dec 2021RevenueNet incomeNet losstallest bar $127.1M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$19.4M
$13.5M
30 Jun 2026
$20.1M
-$26.8M
31 Mar 2026
$21.1M
$127.1M
31 Dec 2025
–
$19.3M
30 Sep 2025
$19.6M
-$34.7M
30 Jun 2025
$21.8M
-$33.5M
31 Mar 2025
$40.8M
-$26.0M
31 Dec 2024
$46.7M
-$34.1M
30 Sep 2024
$45.0M
-$26.9M
30 Jun 2024
$37.2M
-$45.7M
31 Mar 2024
$45.5M
-$32.2M
31 Dec 2023
$28.2M
-$19.8M
30 Sep 2023
$25.4M
-$21.0M
30 Jun 2023
$27.7M
-$17.0M
31 Mar 2023
$25.1M
-$16.8M
31 Dec 2022
$27.0M
-$20.8M
30 Sep 2022
$25.6M
-$29.4M
30 Jun 2022
$18.8M
-$63.5M
31 Mar 2022
$26.5M
-$76.3M
31 Dec 2021
$38.3M
-$9.4M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$84.4M
$108.3M
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
-22%
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$133.1M
-$128.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$0.34
-$0.33
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
52.2%
49.0%
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
-97.5%
-109%
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
158%
-118%
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
27.9%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
-$98.4M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$461.1M
$194.9M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$300K
$299K
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$460.8M (net cash)
-$194.6M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.00
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$1.41
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
–
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
3.0
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.45
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$47K
bought $47K, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-26%
104 13F filers vs 140
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
73%
289.4M shares held by 13F filers (30 Sep 2026) of 394.8M outstanding (1 Nov 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
0.5%
2.2M shares sold short (30 Oct 2026) of 394.8M outstanding (1 Nov 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.1
2.2M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-11%
2.4M shares sold short in the report before, 2.2M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
75%
75% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 42%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
-0.9%
$19.4M vs $19.6M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-82%
$344K vs $1.9M (quarter ended 30 Jun 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$850K
the 12 months before: $398K
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
15
15 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
–
15 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.
Price $0.63 on 20 Nov 2026, -51% over 12 months (12-month range $0.54 to $1.68)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders bought a net $550K in the last 12 months (the 12 months before: $20.9M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 6 published in the last 12 months, +500% on the 12 months before.Revenue per quarter. Revenue $19.4M in the latest quarter, -0.9% on a year earlier.Capital spending per quarter. Capital spending $344K in the latest quarter, -82% on a year earlier.Institutional holders (13F filers). 104 13F filers reported holding it in the latest 13F quarter, -28% on a year earlier.Federal obligations. Federal obligations: $205K published in the last 12 months, -80% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: lobbying spend, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $38.3M, -14% on a year earlier; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $26.5M, -19% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $18.8M, -39% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $25.6M, -10% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $27.0M, -29% on a year earlier; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $25.1M, -5.2% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $27.7M, +47% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $25.4M, -1.1% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $28.2M, +4.3% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $45.5M, +81% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $37.2M, +34% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $45.0M, +77% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $46.7M, +66% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $40.8M, -10% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $21.8M, -42% on a year earlier; public on 16 Aug 2025
Quarter ended 30 Sep 2025: $19.6M, -57% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Mar 2026: $21.1M, -48% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $20.1M, -7.6% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $19.4M, -0.9% on a year earlier; public on 4 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $463K; public on 9 Mar 2022
Quarter ended 31 Mar 2022: $868K, -87% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $938K, -78% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.3M, -26% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $755K, +63% on a year earlier; public on 15 Mar 2023
Quarter ended 31 Mar 2023: $1.0M, +16% on a year earlier; public on 10 May 2023
Quarter ended 30 Jun 2023: $838K, -11% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $905K, -28% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $78K, -90% on a year earlier; public on 2 Mar 2024
Quarter ended 31 Mar 2024: $781K, -23% on a year earlier; public on 10 May 2024
Quarter ended 30 Jun 2024: $1.9M, +131% on a year earlier; public on 7 Aug 2024
Quarter ended 30 Sep 2024: $2.3M, +149% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $3.4M, +4236% on a year earlier; public on 12 Mar 2025
Quarter ended 31 Mar 2025: $5.1M, +547% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.9M, -2.6% on a year earlier; public on 16 Aug 2025
Quarter ended 30 Sep 2025: $886K, -61% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $476K, -86% on a year earlier; public on 17 Mar 2026
Quarter ended 31 Mar 2026: $570K, -89% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $344K, -82% on a year earlier; public on 6 Aug 2026
Institutional holders (13F filers)
31 Dec 2021 report: 111; public on 14 Feb 2022
31 Mar 2022 report: 101; public on 16 May 2022
30 Jun 2022 report: 86; public on 15 Aug 2022
30 Sep 2022 report: 64; public on 14 Nov 2022
31 Dec 2022 report: 66; public on 14 Feb 2023
31 Mar 2023 report: 65; public on 15 May 2023
30 Jun 2023 report: 67; public on 14 Aug 2023
30 Sep 2023 report: 71; public on 14 Nov 2023
31 Dec 2023 report: 82; public on 14 Feb 2024
31 Mar 2024 report: 141; public on 15 May 2024
30 Jun 2024 report: 138; public on 14 Aug 2024
30 Sep 2024 report: 137; public on 14 Nov 2024
31 Dec 2024 report: 142; public on 14 Feb 2025
31 Mar 2025 report: 145; public on 15 May 2025
30 Jun 2025 report: 152; public on 14 Aug 2025
30 Sep 2025 report: 145; public on 14 Nov 2025
31 Dec 2025 report: 150; public on 17 Feb 2026
31 Mar 2026 report: 150; public on 15 May 2026
30 Jun 2026 report: 140; public on 14 Aug 2026
30 Sep 2026 report: 104; public on 16 Nov 2026
Federal obligations
Month from 1 Dec 2021: $0 published
Month from 1 Feb 2022: $47K published
Month from 1 Mar 2022: $53K published
Month from 1 Apr 2022: -$26K published
Month from 1 May 2022: -$2K published
Month from 1 Jun 2022: $34K published
Month from 1 Jul 2022: $21K published
Month from 1 Aug 2022: $356K published
Month from 1 Sep 2022: $244K published
Month from 1 Dec 2022: $61K published
Month from 1 Mar 2023: $155K published
Month from 1 Apr 2023: $21K published
Month from 1 May 2023: $18K published
Month from 1 Jun 2023: $0 published
Month from 1 Jul 2023: $230K published
Month from 1 Aug 2023: $147K published
Month from 1 Sep 2023: $125K published
Month from 1 Feb 2024: $55K published
Month from 1 Mar 2024: -$1K published
Month from 1 Apr 2024: -$167K published
Month from 1 May 2024: $78K published
Month from 1 Jun 2024: $113K published
Month from 1 Jul 2024: $33K published
Month from 1 Aug 2024: $14K published
Month from 1 Sep 2024: $169K published
Month from 1 Dec 2024: -$8K published
Month from 1 Mar 2025: $56K published
Month from 1 Apr 2025: $86K published
Month from 1 Jun 2025: $16K published
Month from 1 Jul 2025: $49K published
Month from 1 Aug 2025: $294K published
Month from 1 Sep 2025: $543K published
Month from 1 Mar 2026: $15K published
Month from 1 Apr 2026: $17K published
Month from 1 Jun 2026: $0 published
Month from 1 Jul 2026: $0 published
Month from 1 Aug 2026: $130K published
Month from 1 Sep 2026: $42K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $344K (30 Jun 2026), 82% below its normal quarter of $1.9M; higher than 22% of its own history.
In 12 months: 5 director or officer changes, 3 major agreements, 2 delisting notices, 1 completed deal. Results releases and routine reports are left out.
Filed
What happened
Source
19 Nov 2026
Stockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closingSame filing: shareholder vote results
Reported lobbying spend: $60K in Q3 2021, $80K in Q2 2021. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
14 May 2024confirmed
Confirmed across sources Institutional holdings and Filings + Financials and Short interest and volume
Standard BioTools(LAB): had 10.2M shares sold short in the 28 Mar 2024 report, 3.8× the same report last year; it also reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year; and it saw 67 13F filers open a new position in the quarter ended 31 Mar 2024, 5.6× the same quarter last year. Three unrelated kinds of activity within 63 days.
Short interest and volume: Short interest spike, became public on 10 Apr 2024
Short interest and volume: Short interest spike, became public on 25 Apr 2024
Financials: Quarterly revenue change, became public on 14 May 2024
Short interest and volume: Short interest spike, became public on 10 May 2024
Institutional holdings: Many funds opening a new position, became public on 15 May 2024
Short interest and volume: Short interest spike, became public on 25 May 2024
Short interest and volume: Short interest spike, became public on 12 Jun 2024
The 28 Mar 2024 report against the 24 reports before it.
this reportearliernormal: 3.3MSee the evidence (7 changes)
Short interest and volume: Short interest spike became public on 10 Apr 2024
Standard BioTools had 10.2M shares sold short in the 28 Mar 2024 report, 3.8× the same report last year.
This period
10.2M (the 28 Mar 2024 report)
Normal report (median of 24 earlier)
3.3M
Typical spread (median absolute deviation)
701K
How far from its usual level
+6.6
Same report last year
2.7M
History used
714 days
the 28 Mar 2024 report24 earlier reportsnormal: 3.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Apr 2024
Standard BioTools had 11.3M shares sold short in the 15 Apr 2024 report, 3.6× the same report last year.
This period
11.3M (the 15 Apr 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
808K
How far from its usual level
+6.5
Same report last year
3.2M
History used
732 days
the 15 Apr 2024 report24 earlier reportsnormal: 3.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 14 May 2024
Standard BioTools reported revenue of $45.5M for the quarter ended 31 Mar 2024, 1.8× the same quarter last year.
This period
$45.5M (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
$26.1M
Typical spread (median absolute deviation)
$951K
How far from its usual level
+7.5
Same quarter last year
$25.1M
History used
5,023 days
the quarter ended 31 Mar 20248 earlier quartersnormal: $26.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 10 May 2024
Standard BioTools had 11.4M shares sold short in the 30 Apr 2024 report, 3.5× the same report last year.
This period
11.4M (the 30 Apr 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
944K
How far from its usual level
+5.6
Same report last year
3.3M
History used
747 days
the 30 Apr 2024 report24 earlier reportsnormal: 3.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Institutional holdings: Many funds opening a new position became public on 15 May 2024
Standard BioTools saw 67 13F filers open a new position in the quarter ended 31 Mar 2024, 5.6× the same quarter last year.
This period
67 (the quarter ended 31 Mar 2024)
Normal quarter (median of 8 earlier)
13
Typical spread (median absolute deviation)
4
How far from its usual level
+9.1
Same quarter last year
12
History used
3,835 days
the quarter ended 31 Mar 20248 earlier quartersnormal: 13
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 25 May 2024
Standard BioTools had 12.1M shares sold short in the 15 May 2024 report, 3.8× the same report last year.
This period
12.1M (the 15 May 2024 report)
Normal report (median of 24 earlier)
3.9M
Typical spread (median absolute deviation)
1.3M
How far from its usual level
+4.4
Same report last year
3.2M
History used
762 days
the 15 May 2024 report24 earlier reportsnormal: 3.9M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 12 Jun 2024
Standard BioTools had 13.3M shares sold short in the 31 May 2024 report, 4.8× the same report last year.
This period
13.3M (the 31 May 2024 report)
Normal report (median of 24 earlier)
4.1M
Typical spread (median absolute deviation)
1.6M
How far from its usual level
+4.0
Same report last year
2.8M
History used
778 days
the 31 May 2024 report24 earlier reportsnormal: 4.1M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
19 Feb 2019confirmed
Confirmed across sources Government contracts and Institutional holdings
Standard BioTools(LAB): won its first federal award in our data, a $1.3M Department of Veterans Affairs contract, while it saw 29 13F filers open a new position in the quarter ended 31 Dec 2018, 3.2× the same quarter last year. Two unrelated kinds of activity within 29 days.
Government contracts: First federal award, became public on 21 Jan 2019
Institutional holdings: Many funds opening a new position, became public on 14 Feb 2019
The quarter ended 31 Dec 2018 against the 8 quarters before it.
this quarterearliernormal: 9See the evidence (2 changes)
Government contracts: First federal award became public on 21 Jan 2019
Standard BioTools won its first federal award in our data, a $1.3M Department of Veterans Affairs contract.
"First" means first in our data: it fires only when the source's history began at least 365 days earlier.
Institutional holdings: Many funds opening a new position became public on 14 Feb 2019
Standard BioTools saw 29 13F filers open a new position in the quarter ended 31 Dec 2018, 3.2× the same quarter last year.
This period
29 (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
2.5
How far from its usual level
+5.4
Same quarter last year
9
History used
1,918 days
the quarter ended 31 Dec 20188 earlier quartersnormal: 9
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
19 Nov 2026Filings change
filed a director or officer change: Stockholders approved Post-Closing Equity Incentive Plan and ESPP, effective at Merger closing.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
spent $5.1M on capital projects in the quarter ended 31 Mar 2025, 6.5× the same quarter last year.
Same quarter last year: $781K; its normal quarter is $958K.
See the evidence
This period
$5.1M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$958K
Typical spread (median absolute deviation)
$528K
How far from its usual level
+4.1
Same quarter last year
$781K
History used
3,287 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $958K
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
reported revenue of $46.7M for the quarter ended 31 Dec 2024, 1.7× the same quarter last year.
Same quarter last year: $28.2M; its normal quarter is $27.9M.
See the evidence
This period
$46.7M (the quarter ended 31 Dec 2024)
Normal quarter (median of 8 earlier)
$27.9M
Typical spread (median absolute deviation)
$2.7M
How far from its usual level
+4.7
Same quarter last year
$28.2M
History used
5,298 days
the quarter ended 31 Dec 20248 earlier quartersnormal: $27.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $45.0M for the quarter ended 30 Sep 2024, 1.8× the same quarter last year.
Same quarter last year: $25.4M; its normal quarter is $27.3M.
See the evidence
This period
$45.0M (the quarter ended 30 Sep 2024)
Normal quarter (median of 8 earlier)
$27.3M
Typical spread (median absolute deviation)
$1.8M
How far from its usual level
+6.4
Same quarter last year
$25.4M
History used
5,206 days
the quarter ended 30 Sep 20248 earlier quartersnormal: $27.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
reported revenue of $37.2M for the quarter ended 30 Jun 2024, 1.3× the same quarter last year.
Same quarter last year: $27.7M; its normal quarter is $26.3M.
See the evidence
This period
$37.2M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$26.3M
Typical spread (median absolute deviation)
$1.3M
How far from its usual level
+4.1
Same quarter last year
$27.7M
History used
5,114 days
the quarter ended 30 Jun 20248 earlier quartersnormal: $26.3M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Showing the newest 40 of 161 entries; narrow the window or the kind of data to see older ones.
Not listed: 166 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0001162194
Ticker
LAB
Domain
standardbio.com
Employer name
Standard BioTools Inc. (1 unverified)
Hq location
MA|BOSTON|02109 (1 unverified)
Lobbying client
fluidigm
Name
FLUIDIGM CORP, SB Sciences Inc., Standard BioTools Australia Pty. Ltd., Standard BioTools Canada Inc. (Ontario, Canada) and 10 more
Uei
Q7U7QSDD32W4
Wikidata
Q19647855
Wikipedia
Standard BioTools
DOL H-1B labor condition applications and PERM certifications48 data points12 Jun 2023 to 31 Aug 2026
Federal lobbying disclosures (LDA)2 records, 20 data points1 Jun 2020 to 31 Dec 2021
SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)207 records12 Jan 2016 to 19 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1253 data points27 Dec 2008 to 1 Nov 2026
SEC Form 4 insider transactions146 records, 532 data points3 Nov 2016 to 5 Nov 2026
FINRA short interest (twice monthly)330 data points14 Apr 2022 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)2324 data points6 Apr 2022 to 20 Nov 2026
USASpending.gov federal awards2 records, 1581 data points2 Oct 2007 to 16 Sep 2026
Wikipedia pageviews1610 data points25 Jun 2022 to 20 Nov 2026